9th Annual Biomarkers Congress
The Next Wave of Antibody Therapeutics
World Trade Center Boston
200 Seaport Boulevard
Boston, MA 02210
The Next Wave of Antibody Therapeutics 
 Drug Discovery 

Schedule of Presentations:

Monday, August 3, 2009
07:30:00 Registration and Coffee
08:30:00 Conference Chair Opening Remarks Ulrik B Nielsen
08:35:00 Antibody-Drug Conjugates and Other Conjugation Strategies
08:40:00 Antibody-Drug Conjugates for Cancer Therapy Paul G. Polakis
09:10:00 Preclinical Development of Novel Antibody-Drug Conjugate Technology Based on Potent DNA Damaging Duocarmycins Vincent de Groot
09:40:00 Development of Antibody-Drug Conjugates Targeting Novel Cancer Targets Aya Jakobovits
10:40:00 PSMA ADC, an Antibody-Drug Conjugate as a Potential Prostate Cancer Treatment and Antineovascular Therapy William C. Olson
11:10:00 Novel Antibody-Drug (mAb-SN-38) Conjugates in Solid Tumor Therapy S.V. Govindan
11:40:00 An Antibody-Cytotoxic Conjugate, BIIB015, is a New Targeted Therapy for Cripto Positive Tumors Michele Sanicola-Nadel
12:10:00 Networking Luncheon with Attendee/Speaker Chat Sessions
12:15:00 Antibody-Drug Conjugates Nils Lonberg
12:15:00 Immunogenicity of Protein Therapeutics in the Clinic William C. Olson
12:25:00 Multispecific or Bispecific Antibody Drugs David M. Goldenberg
12:30:00 Considerations When Optimizing Therapeutic Antibodies for Specific Disease Indications Sanjay D. Khare
12:35:00 Pharmacodynamic Biomarkers of Antibodies Frank Calzone
13:30:00 Targeting B-Cell Lymphomas with Inotuzumab Ozogamicin (CMC-544), an Anti-CD22 Immunoconjugate Erik R. Vandendries
14:00:00 MDX-1203: A CD70 Directed Antibody-Drug Conjugate Comprising a Novel Highly Potent Alkylating Agent Nils Lonberg
14:30:00 IMGN901: An Active Maytansinoid Conjugate Targeting CD56 John M. Lambert
15:00:00 Networking Refreshment Break
15:30:00 SGN-35 and SGN-75: Development of Antibody-Drug Conjugates for the Treatment of Cancer Jonathan G. Drachman
16:00:00 CR011-vcMMAE, an Antibody-Drug Conjugate for the Treatment of Melanoma and Breast Cancer Ronit Simantov
16:30:00 Clinical Results of the Phase I and Phase II Studies of Trastuzumab-DM1, A First-in-class HER2 Antibody-Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer Barbara Klencke
17:00:00 Strategic Discussion GroupAntibody-Drug Conjugates and Other Approaches to Enhance Efficacy and Potency Nils Lonberg
17:30:00 Close of Day One
18:00:00 Attendee Networking Dinner
Tuesday, August 4, 2009
08:10:00 Conference Chair Opening Remarks William Dall' Acqua
08:15:00 Approaches to Improve Antibody Efficacy and Potency
08:15:00 Optimizing Targeted Anti-tumor Biologics with Immune Effector Molecules Sanjay D. Khare
08:40:00 Optimizing Antibody Efficacy, Effector Selectivity, and Half-life with Fc Engineering John R. Desjarlais
09:05:00 Biologics for the Treatment of Respiratory Diseases; A Place for Anti-IL-9, Anti-IL5R and Anti-IL-13 Therapies in Bronchial Asthma Alison Humbles
09:30:00 T Cell Engaging BiTE Antibodies: Clinical Proof of Concept and Recent Developments Tobias Raum
09:35:00 Bispecific and Multispecific Drugs
09:55:00 Multi-Specific Adnectins: Realizing the Promise of a Novel Class of Targeted Biologics Sharon Cload
10:20:00 Networking Refreshment Break in Exhibit & Poster Hall
11:00:00 MM-111: A Novel Bispecific Antibody Targeting ErbB3 with Potent Anti-tumor Activity in ErbB2 Over-expressing Malignancies Charlotte McDonagh
11:25:00 DVD-Ig™: A Novel Dual-Targeting Technology Tariq Ghayur
11:50:00 Selection of Stable Single-chain Variable Fragments for Assembly of Anti-PDGFRB/VEGFA Dual-targeting Proteins Robert Mabry
11:55:00 Strategic Discussion Group
12:15:00 Challenges and Risks of Developing Antibodies and Biologics in New Formats Eric Furfine, Tobias Raum, John R. Desjarlais, Ulrik B Nielsen
12:40:00 Networking Luncheon in Exhibit & Poster Hall
12:45:00 Combination Strategies to Enhance Antibody Therapies
12:55:00 Conference Keynote
14:00:00 Antibody Combinations Targeting erbB Receptors in Solid Tumors Mark D. Pegram
14:25:00 Combination and Bispecific Anti-CD20/CD22 Immunotherapy David M. Goldenberg
14:50:00 Combinatorial Strategies for Tumor Inhibition using AMG 479, a Fully Human Monoclonal Antibody that Inhibits the Insulin-like Growth Factor (I) Receptor (IGF-1R) Frank Calzone
15:15:00 Quantitative Prediction of Anti-tumor Antibody Macro and Microdistribution Karl Dane Wittrup
15:40:00 Networking Refreshment Break in Exhibit & Poster Hall
15:45:00 Pharmacodynamic Biomarkers in Antibody Development
16:25:00 Clinical Development of the IGF-IR inhibitor Figitumumab for the Treatment of Cancer Antonio Gualberto
16:50:00 Pharmacodynamic Approach in Early Trials with an Anti-Interferon-a Monoclonal Antibody in Lupus Barbara White
17:15:00 Close of Antibody Therapeutics Main Conference and Proceed to Plenary Keynote
17:20:00 Keynote Introduction Osamu Sato
17:20:00 Plenary Keynote
17:25:00 Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market Takashi Shoda
18:00:00 Cocktail Reception in Exhibit & Poster Hall
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.